

# **MASTERING THE PRIOR AUTHORIZATION PROCESS: Assuring the Best Care for Your Patients**

A blue sphere on a stand, standing out from a field of white spheres. The blue sphere is positioned in the upper right quadrant of the image, and it is the only one of its color. It is on a dark blue stand. The white spheres are arranged in a grid-like pattern, filling the background. The blue sphere has the text "Stand Out in your care" written on it in a white, serif font.

Stand Out  
in your care

Jill Young – CEMA, CPC, CEDC, CIMC  
Young Medical Consulting, LLC  
East Lansing, Michigan

This material is designed to offer basic information for coding and billing. The information presented here is based on the experience, training, and interpretation of the author. Although the information has been carefully researched and checked for accuracy and completeness, the instructor does not accept any responsibility or liability with regard to errors, omissions, misuse, or misinterpretation. This handout is intended as an educational a guide and should not be considered a legal/consulting opinion




“Few words arouse more frustration among primary care physicians than ‘prior authorization.’”

*-Medical Economics, October 2013*



- Denial of a Prior Authorization is not denial of the **TREATMENT**
- It is a denial of **PAYMENT**



- Prior authorization: In pharmacy, a cost-containment procedure that requires a prescriber to obtain permission to prescribe a medication prior to prescribing it.
- Also called prior approval

• MedicineNet

**Prior Authorizations**



- Prior authorization (PA) is any process by which physicians and other health care providers must obtain advance approval from a health plan before a specific procedure, service, device, supply or medication is delivered to the patient to qualify for payment coverage.
- Other terms used by health plans for this process include:
  - Preauthorization
  - Precertification
  - Prior approval
  - Prior notification
  - Prospective review
  - Prior review

## Prior Authorizations



- Health plans :
  - Often used to restrict access to costly services and therapies
    - Particularly newer treatments
  - Also use to ensure that a therapy is appropriate and safe for a specific patient
    - Require kidney function laboratory results prior to approval of a medication contraindicated in patients with renal failure.

• AMA<sup>©</sup>


**Prior Authorizations**



- Seen as a roadblock to patients receiving necessary treatment



- Unnecessary questioning of their medical judgement and clinical expertise



**Physicians View**



- Delays in patient care
- Uncompensated work for physicians and staff, which translates into increased overhead costs for practices
- Disruption in practice workflow
- Nonpayment if Prior Authorization not completed in advance of service provision

**What are Consequences of Prior Authorization process?**



86% physicians described the administrative  
burden as

“high or extremely high”

88% - burden has gone up in the last five years

AMA Survey 2018




- 66% of prescriptions rejected by insurance require a prior authorization
- 33% of those scripts are abandoned

• CoverMyMeds®




- *91% Physicians reported that Prior Authorizations can have a negative effect on clinical outcomes*
- *75% Physicians reported that Prior Authorizations delays lead to patients abandoning treatment*
- *28% Physicians reported that Prior Authorizations have led to a serious adverse event such as hospitalization, disability or death for a patient in their care*

• AMA Survey 2018



## Increasing use of PA: Medicare Part D

### Percentage of Covered Drugs Requiring PA




Sources: NORC/Social & Scientific Systems analysis of data from CMS; *Medicare Part D Prescription Drug Plans: The Marketplace in 2013 and Key Trends, 2006-2013*. Available at: <http://kff.org/medicare/issue-brief/medicare-part-d-prescription-drug-plans-the-marketplace-in-2013-and-key-trends-2006-2013/>.

- Obtain copies of major insurance formularies
  - Create your own if needed



**Formulary**

# EXAMPLES



cc 236  
Davlin

AUG 27 2019

Dear Valued Provider:

The enclosed information was sent to your patient.

If you have any questions, or would like to discuss our decision to deny this request for prior authorization with a reviewing physician or pharmacist, please call PerformRx Provider Services at 1-888-989-0057, Monday through Friday from 8:30a.m. to 6 p.m. TTY users should call 1-888-989-0057.

Our criteria for this decision is available upon request.

Sincerely,

Pharmacy Management

Enclosure: Member Denial Notice  
Grievance and Appeal Fact Sheet



Dear [REDACTED]:

Blue Cross Complete of Michigan has reviewed the request for SYMBICORT 160-4.5 MCG INHALER, # 30.6. On 8/22/2019, Davin [REDACTED] submitted this request for [REDACTED]. A pharmacist has reviewed this request.

**This request is denied:** according to our Prior Authorization Criteria for Non-Formulary Inhalers.

The authorization request from your doctor doesn't meet our criteria for inhalers that aren't on our formulary. This criteria says:

- SYMBICORT 160-4.5 MCG INHALER must be approved for the treatment of your condition AND
- the dose must be approved for the treatment of your condition and age AND
- you must first try 2 formulary inhalers in the same class (if available) OR
- you have a medical, physical, or other condition that makes it difficult to use a formulary inhaler (for example you need to use a spacer and our formulary inhaler can't be used with a spacer)

We can't approve this request because our records show that you haven't tried two of our formulary inhalers such as Wixela Inhub (generic Advair Diskus), Serevent Diskus or with step therapy: Bevespi Aerosphere. If you have and they didn't work, ask your doctor to provide medical records showing that you have tried two formulary inhalers.

If the other inhalers cannot be used, and your doctor can give us more information to support their decision to use SYMBICORT 160-4.5 MCG INHALER, we may change our decision. This information can include more medical history and guideline information for your condition.

Our Prior Authorization Criteria for Non-Formulary Inhalers is available upon request..

Prescriber:

Tel: (517)

Please refer to the pharmacist comments and the information below when processing this request.

Pharmacist Comments:

Patient Info:

Pharmacy Info:

RITE AID

TEL:

FAX:

Prescription Info:

Rx # 17262

Date Filled: 08/26/2019

DEXTROAMP-AMPHETAMIN 30 MG TAB

Qty / Day Supply: 60.000 / 30

take 1 tablet by mouth twice a day

Patient Insurance Info:

THIRD PARTY AGENCY: MIHEALTH CARD <BIN#009737>

ID: 0038503503

GROUP:

Agency Reject Messages:

MIHEALTH CARD <BIN#009737> - 75: Prior Authorization Required. See Third Party Information.

Information: Additional agency message: MIHEALTH CARD <BIN#009737> - Call 877-864-9014 Under 6 and over 17 requires a PA

Please complete the appropriate response and contact the pharmacy via phone/fax.

Date: \_\_\_/\_\_\_/\_\_\_ Authorization Approved

Authorization Denied

Comments:

## PRESCRIPTION REQUIRES A PRIOR AUTHORIZATION

This prescription was rejected by the patient's PBM. You have the choice to change the drug according to the patient's formulary or call for a prior authorization. Please call the number provided on the third party reject details if available. Otherwise contact the pharmacy for details.

### RETURN PRIOR AUTHORIZATION TO:

PHONE: (517)  
FAX: (517)

### PATIENT INFORMATION:

PHONE:

### PRESCRIPTION INFORMATION:

Patient:  
Doctor:  
Drug: SPIRIVA HANDIHLR CAP BOEH  
NDC: 00397007541

### REJECT INFORMATION:

NON-FORMULARY DRUG, CONTACT PRESCRIBER (PHARMACY HELP DESK 1-866-281-0635)  
Processor/PBM Help Desk: 8662810635

### ADJUDICATION RESULTS:

MR DRUG NOT ON FORMULARY  
569 PROVIDE MEDICARE RX DRUG COVG & RIGHT

### PRIOR AUTH APPROVAL:

☐ Change Drug:  
☐ New SIG if needed:

☐ New Prescriber  
☐ DISPENSE AS WRITTEN


Physician's Signature: \_\_\_\_\_

Date: \_\_\_\_\_

\*\*\*\*\*  
PRESCRIPTION REQUIRES A PRIOR AUTHORIZATION  
Please notify pharmacy when prior authorization is approved.

*OK - give in option*

# KNOW YOUR CLINICAL GUIDELINES



[About](#)[Solutions](#)[Patients](#)[Provider's Hub](#)[Insights](#)[Careers](#)[Contact Us](#)[Search](#)[PROVIDERS:](#)[Check Prior Authorization Status](#)[Login](#)[Resources](#)[Cardiology & Radiology](#)[Gastroenterology](#)[Laboratory Management](#)[Medical Oncology](#)[Musculoskeletal: Advanced Procedures](#)[Musculoskeletal: Therapies](#)[Radiation Oncology](#)[Sleep Management](#)[Specialty Drug Management](#)[Post-Acute Care](#)[Durable Medical Equipment](#)

# How to Avoid Peer to Peer Phone Calls

## The “Keys” to Prior-Auth



### Key #1

#### Download eviCore's Guidelines

Check out the eviCore guidelines. We use a rigorous process of accumulating and assessing the best available evidence, in accordance with the standards of our accreditation agencies (URAC and NCQA). In short, each chapter in the eviCore guidelines reflects the most current and authoritative evidence-based recommendations created by well-respected national organizations and made available to the public.



## Key #2

### Provide Clinical Information Up Front


To avoid denials and P2Ps, be proactive; anticipate and prepare the clinical information that eviCore will likely need, and provide that information to your prior-authorization employee to get approval during the initial request.



## Key #3

### Prepare for Clinical Questions

The fastest and most reliable way to avoid P2P phone calls and other appeals and obtain the prior authorization number "right out of the gate" on the very first submission is to be prepared to answer the clinical questions that will be asked.



## Key #4

### Refer to the Guidelines

Paste the eviCore guidelines on your desktop and refer to them whenever you are uncertain about the best imaging study request when you are treating your patients.





The AIM Specialty Health Clinical Appropriateness Guidelines and Cancer Treatment Pathways are clinical tools designed to help providers choose the most appropriate treatments and tests for health plan members with complex clinical needs.



## RADIOLOGY

Guidelines for imaging modalities, including CT, MRI, MRA, and PET. Also available are guidelines for pediatric imaging.

[FIND THE GUIDELINES →](#)


## CARDIOLOGY

Guidelines for cardiac imaging modalities, including echocardiography, nuclear cardiology, cardiac CT, cardiac MRI, cardiac PET, and arterial ultrasound.

[FIND THE GUIDELINES →](#)


## SLEEP

Guidelines for testing and treatment of sleep disorders, including obstructive sleep apnea.

[FIND THE GUIDELINES →](#)


## RADIATION ONCOLOGY

Guidelines for radiation therapies, including brachytherapy, image-guided radiotherapy (IGRT), intensity-modulated radiation therapy (IMRT), and proton beam therapy.

[FIND THE GUIDELINES →](#)


## MUSCULOSKELETAL

Guidelines for spine surgeries, joint surgeries, and interventional pain management.

[FIND THE GUIDELINES →](#)


## GENETIC TESTING

Guidelines for genetic testing, including for pharmacogenomics, prenatal diagnosis, cardiac disease, cancer susceptibility, and tumors and malignancies.

[FIND THE GUIDELINES →](#)



## Indications For In-Lab (Attended) Sleep Studies In Adult Patients (Age 19 Years or Older)

### Suspected OSA (in patients with unspecified sleep apnea and nocturnal desaturation, OSA should be suspected and excluded if clinically appropriate):

An in-lab sleep (attended) study is indicated if the patient meets any of the following criteria (1–3) **AND** has a contraindication to a home sleep study (as listed in table above):

1. Observed apneas during sleep; **OR**
2. A combination of **at least two (2)** of the following (a–e):
  - a. Excessive daytime sleepiness evidenced by an Epworth sleepiness scale score greater than ten (10), inappropriate daytime napping (e.g., during driving, conversation, or eating), or sleepiness that interferes with daily activities and is not explained by other conditions;
  - b. Habitual snoring or gasping/choking episodes associated with awakenings;
  - c. Treatment-resistant hypertension (persistent hypertension in a patient taking three or more antihypertensive medications);
  - d. Obesity, defined as a body mass index greater than 30 kg/m<sup>2</sup> or increased neck circumference defined as greater than seventeen (17) inches in men or greater than sixteen (16) inches in women;
  - e. Craniofacial or upper airway soft tissue abnormalities, including adenotonsillar hypertrophy, or neuromuscular disease; **OR**




Clinical & Regulatory Guidelines  
8600 W Bryn Mawr Avenue  
South Tower - Suite 800  
Chicago, IL 60631  
P. 773.864.4600  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)



## Suspected sleep disorder other than OSA

An in-lab supervised sleep study is appropriate when there is suspicion of any of the following (1–7):

1. Central sleep apnea
  2. Narcolepsy
  3. Nocturnal seizures
  4. Parasomnia
  5. Idiopathic hypersomnia
  6. Periodic limb movement disorder (PLMD) – In order to support the suspicion of PLMD in this context, one of the following (i–vi) must be documented: (i) Pregnancy, (ii) Renal failure, (iii) Iron deficiency anemia, (iv) Peripheral neuropathy, (v) use of antidepressant or antipsychotic medications, or (vi) continued hypersomnia and clinical symptoms of PLMD after sleep disordered breathing is ruled out by home sleep testing.
- 



Clinical & Regulatory Guidelines  
8600 W Bryn Mawr Avenue  
South Tower - Suite 800  
Chicago, IL 60631  
P. 773.864.4600  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

- Expedite process
  - Patient gets care sooner
  - Avoid delays in testing/treatment
- Allows staff to aid in process
- Include in note for today
  - Succinctly documenting
    - Specific details
    - Dates and services/medications



**Know What Information Is Needed**

- Time saving in overall process
- Time NOT spent by you
- Cost saving
  - Physician vs Staff \$\$

**Know What Information Is Needed**



- Know your practice
  - What medications require Prior Authorizations?
    - May differ by insurance carrier
    - Does your EHR system help
    - Succinctly placing information in today's chart record helps make meeting conditions easy to submit to carrier
  - Create a Master Grid of information

*For this medication patient  
must have*

- failed on Inhaler A*
- failed on Inhaler B*

**How To Combat Delays to Patient Treatment  
- Prior Authorization for Medications**




- Know your practice
  - What Tests/Treatment require Prior Authorizations?
    - May differ by insurance carrier
    - Does your EHR system help
    - Succinctly placing information in today's chart record helps make meeting conditions easy to submit to carrier
  - Create a Master Grid of information

*For this CT scan, patient must have had Signs & Symptoms for 6 months with a negative x-ray within the past 30 days*


**How To Combat Delays to Patient Treatment  
- Prior Authorization for Testing/Treatment**



- Check coverage PRIOR to issuing script or ordering test
- Establish protocol
  - Avoid delays in patient care
  - Prevent potential follow-ups with patients for additional information
- Track progress
  - Avoid delays in patient care
  - Prevent delays “waiting” for “call back”
- Submit documentation



# GOING FORWARD





- 83% of survey respondents request PA using faxes
  - 63% use a paper form
  - 35% direct through a payer Web site
  - 14% use an electronic standard transaction either through their practice management system or an electronic medical record

• AMA/Federation 2010 Survey


**Automation Needed**



- Have a discussion about the most expensive way to get a test done
  - Send the patient to the Emergency Room, who will most likely order and get the test performed
    - Additional expense of Emergency room and emergency physician
  - Send the patient to another doctor, a specialist who will probably order the test
    - Additional expense of additional doctor – something you are explaining you would avoid


**Playing Hard Ball**

synonyms for playing hardball:  
useful, impressive, efficient, sufficient, powerful,  
direct, potent, practical, competent, valid




- Ask the insurance's physician their name
- Tell them:
  - You are going to document in the patient's record of their denial of the test you are trying to get approval for
  - That information (the denial, the doctors name, the phone number you called) will be in the clinical summary that the patient receives for completeness of documentation
- The insurance's physician will say they have no liability

**Playing Hard Ball**




- Check your participation contract



Playing Hard Ball

synonyms for playing hardball:  
useful, impressive, efficient, sufficient, powerful,  
direct, potent, practical, competent, valid




- Overall reduction in health plans' use of Prior Authorizations
- Limitation of Prior Authorizations
  - True utilization outliers vs. current broadly applied programs
- Exploration of alternative approaches to address utilization issues
- Implementation of standardized electronic transactions when Prior Authorizations is used




- National Committee on Vital and Health Statistics recommended that the Department of Health and Human Services
  - Mandate the NCPDP SCRIPT Standard Version 2013101 ePA transactions as the adopted standard for the exchange of Prior Authorization information for the pharmacy benefit
  - Adopt the ePA transactions “under the most appropriate regulatory sections and processes that would enable prompt industry implementation and at the earliest possible implementation time”
- Unclear if ePA transactions will be mandated as national standard under Health Insurance Portability and Accountability Act (HIPAA) or Medicare Modernization Act (MMA)

• May 15, 2014

- National Council for Prescription Drug Programs (NCPDP) created a suite of electronic transactions to support automated pharmacy PA (ePA)
- 
- ePA transactions are part of NCPDP SCRIPT standard for electronic prescribing and reuse SCRIPT functions and elements
- Approved and published by NCPDP in 2013



- HHS staff have indicated that proposed rule on ePA transactions will be released soon
- NCPDP has recommended that the effective date for compliance with the ePA transactions be 18 months following the final rule



**Future of ePA Federal Mandate**



- *PA sunset programs*
  - PA requirements removed for services with universally high PA approval rates
- *“Gold card” programs*
  - Physicians with high rates of PA approvals over a specified period of time are exempt from PA requirements
- *PA waivers*
  - Physicians using approved, clinically based appropriate use criteria (AUC) and/or clinical decision support excluded from PA programs




- Ask health plans to offer PA automated tools that will integrate with your practice management system (PMS) and EHR—and use them
- Request that your PMS/EHR vendors offer automated PA functionalities that use standard electronic transactions and fit in your practice's workflow


**Alternatives**



- Display current PA requirements, including clinical criteria, on their websites and make this information available to all stakeholders
- Provide contracted health care providers notice of 60 days before implementing a new PA requirement or amending current requirements
- Display statistical information regarding PA approvals and denials on their Web site



- Respond to PA requests in 2 business days for non-urgent services, one business day for urgent services and 60 minutes for post evaluation or post-stabilization services following emergency care
- Offer ePA as an option for physicians



- Also prevents utilization-review entities from:
  - Requiring PA for emergency services
  - Engaging in restrictive step-therapy requirements at the expense of patients' health
  - Revoking or restricting a PA for a period of 45 working days from the date the health care provider received the PA

**Prior Authorization Act  
Ensuring Transparency**




НОРД



- Response Time:
  - 24 hours for urgent services
  - Within 5 days for non-urgent services
- 1 year coverage of prescriptions for chronic-condition maintenance drugs
  - Any change in dosage during this period will be covered
- Prior Authorization procedures will be posted online as well as a complete list of services requiring Prior Authorization
- Insurer Prior Authorization reviewers
  - Licensed physicians
    - When possible, of the same specialty as the requesting physician
- Physicians and other clinicians will be able to electronically request and transmit Prior Authorizations.

**State of Kentucky – Passed :March 2019**  
**Effective: January 1, 2020**



- A health insurer that requires prior authorization shall
  - Use the uniform prior authorization forms developed by the office for medical care, for pharmaceutical benefits or related benefits
  - Establish electronic portal system for electronic and secure transmittal of prior authorization requests
    - 24 hour 7 day per week
      - Medical care
      - Pharmaceutical benefits
      - Related benefits
  - by January 1, 2021
    - Auto-adjudication of prior authorization requests


**State of New Mexico:**  
**Proposed January 4, 2019**  
**Passed: April 4, 2019**  
**Effective : September 1, 2019**






- An adjudication shall be made within twenty-four hours
- Or shall be deemed granted if not made within twenty-four hours, when a covered person's health care professional requests an expedited prior authorization and submits to the health insurer a statement that, in the health care professional's opinion that is based on reasonable medical probability, delay in the treatment for which prior authorization is requested could:
  - (a) seriously jeopardize the covered person's life or overall health
  - (b) affect the covered person's ability to regain maximum function or
  - (c) subject the covered person to severe and intolerable pain

**State of New Mexico:**  
**Proposed January 4, 2019**  
**Passed: April 4, 2019**  
**Effective : September 1, 2019**




- After December 31, 2020, an insurer may automatically deny a covered person's prior authorization request that is electronically submitted and that relates to a prescription drug that is not on the covered person's health benefits plan formulary
  - Provided that the insurer shall accompany the denial with a list of alternative drugs that are on the covered person's health benefits plan formulary.
- Non-compliance fine \$5,000.00

**State of New Mexico:**  
**Proposed January 4, 2019**  
**Passed: April 4, 2019**  
**Effective : September 1, 2019**



- Denial of a Prior Authorization is not denial of the **TREATMENT**
- It is a denial of **PAYMENT**



# Sleep Disorder Management Diagnostic & Treatment Guidelines


## Clinical Appropriateness Guidelines

**Effective Date: June 29, 2019**

Approval and implementation dates for specific health plans may vary. Please consult the applicable health plan for more details.  
AIM Specialty Health disclaims any responsibility for the completeness or accuracy of the information contained herein.

**Proprietary**

providers and reviewers to the most appropriate services based on a patient's unique circumstances. In all cases, clinical judgment consistent with the standards of good medical practice should be used when applying the Guidelines. Guideline determinations are made based on the information provided at the time of the request. It is expected that medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition. The treating clinician has final authority and responsibility for treatment decisions regarding the care of the patient and for justifying and demonstrating the existence of medical necessity for the requested service. The Guidelines are not a substitute for the experience and judgment of a physician or other health care professionals. Any clinician seeking to apply or consult the Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment.



AIM executive leadership team

The executive leadership team manages AIM's day-to-day operations, develops innovative solutions, and strategies that drive AIM's growth, profitability, and innovation.



Brandon Wm. Cadiz

President and Chief Executive Officer. Brandon Cadiz joined AIM in 2017 as its second CEO. He has led AIM's growth initiatives, has expanded the business footprint of the segment and made successful specialty health management companies in South-East Asia.



Robert Mandel, MD, MBA

Robert Mandel, MD, MBA, serves as clinical co-chair of AIM's advisory board. He has led AIM's clinical operations and is a successful leader in the specialty health management industry.



Nancy Armatas

Nancy Armatas is the Senior Vice President and Chief Administrative Officer at AIM. She has led AIM's administrative operations and is a successful leader in the specialty health management industry.



Sam George

Sam George is the Senior Vice President of Operations and Management at AIM. He has led AIM's operational initiatives and is a successful leader in the specialty health management industry.



Lisa Hu

Lisa Hu is the Senior Vice President of Operations and Management at AIM. She has led AIM's operational initiatives and is a successful leader in the specialty health management industry.



Fred Kanutz

Fred Kanutz is the Senior Vice President of Operations and Management at AIM. He has led AIM's operational initiatives and is a successful leader in the specialty health management industry.



Michael Backus

Michael Backus is the Senior Vice President of Operations and Management at AIM. He has led AIM's operational initiatives and is a successful leader in the specialty health management industry.



Joel Cesario

Joel Cesario is the Senior Vice President of Operations and Management at AIM. He has led AIM's operational initiatives and is a successful leader in the specialty health management industry.



Steven J. Fox

Steven Fox is the Senior Vice President of Operations and Management at AIM. He has led AIM's operational initiatives and is a successful leader in the specialty health management industry.



Darin K. McDonald

Darin K. McDonald is the Senior Vice President of Operations and Management at AIM. He has led AIM's operational initiatives and is a successful leader in the specialty health management industry.



Julie Thiel, MD

Julie Thiel, MD, is the Senior Vice President of Operations and Management at AIM. She has led AIM's operational initiatives and is a successful leader in the specialty health management industry.





## AIM clinical leadership team

Our clinical leaders have extensive experience in practicing physician organizations, including as medical directors. Together, the team is committed to advancing physician organizations and our patients' clinical and business outcomes.



**Stacey Barr, MD**

Stacey Barr, MD, serves as the Medical Director of the Medical Strategy Division. She provides clinical leadership in the development of AIM Clinical Strategy Programs. She played an integral role leading the clinical process during the implementation of our solutions for Medical Strategy and Evaluation Program.

[Learn More](#)



**Chris Buckle, MD, MBA, FRCPC**

Chris Buckle, MD, serves as the Medical Director of the Medical Strategy Division. He is responsible for defining the clinical strategy of our Target Population.

[Learn More](#)



**Varsha Chandramouli, MD**

Varsha Chandramouli, MD, is the Vice President, Clinical Operations for AIM. She is responsible for overseeing the physician and organizational success in AIM.

[Learn More](#)



**Thomas P. Power, MD, FACC, MRCPI, MBA**

Thomas Power, MD, is the Senior Medical Director of Cardiology and Heart Medicine for AIM. He is responsible for the clinical development of the Cardiology and Heart Medicine Division.

[Learn More](#)



**Kerrie Reed, MD**

Kerrie Reed, MD, serves as the Medical Director for the AIM Medical Strategy Division. She is responsible for developing the clinical strategy for our Medical Strategy Division. She also oversees the implementation, engagement and growth initiatives.

[Learn More](#)



**Richard Valdesuso, MD, MBA, MA**

Richard Valdesuso, MD, serves as the Medical Director of the AIM Medical Strategy Division. He is responsible for overseeing the clinical strategy of the division.

[Learn More](#)



**Jennifer Eklund, MD**

Jennifer Eklund, MD, serves as the Associate Medical Director of Government Programs for AIM. She is responsible for providing clinical leadership and guidance to the clinical and operational strategy of Government Programs, including Medicare, Medicaid, and Private Payers Program (PPP).

[Learn More](#)



**Michael J. Fisch, MD, MPH, FACP, FAAPM, FASCO**

Michael Fisch, MD, serves as the Medical Director of Medical Strategy Programs and Division for AIM. He is responsible for providing clinical leadership to the clinical and operational strategy of the AIM Medical Strategy Division and the AIM Medical Strategy Division.

[Learn More](#)



**Robert Purno, MD, MPH, MBA, FACEP**

Dr. Purno is the Medical Director of Government Programs (Medicare) for AIM. He is responsible for providing clinical leadership to the clinical and operational strategy of the AIM Government Programs (Medicare) Division.

[Learn More](#)



**Robert P. Zimmerman, MD**

Robert Zimmerman, MD, serves as the Medical Director of Medical Strategy at AIM. He is responsible for providing clinical leadership and guidance to the clinical and operational strategy of the AIM Medical Strategy Division.

[Learn More](#)



**John J. Arlotta**

*President, eviCore healthcare*



**David Smith**

*President, Medical Benefits Management*



**Andy Ellert**

*President, Growth and Innovation*



**Kathleen Mercier**

*EVP and Chief People & Talent Officer*



**Laurie Johnson**

*EVP Chief Legal and Compliance Officer,  
and Corporate Secretary*



**Ellen Clarke**

*Chief Information Officer*



**Elias G. Wahesh**

*EVP Corporate Operations*

**eviCore**





## Associate Medical Directors

---

Our Associate Medical Directors are empowered to make a difference in people's lives by improving the quality of care for patients, providers, and payers. This team reviews clinical requests. Physicians review cases on the eviCore portal or on peer-to-peer calls to determine the appropriate evidence-based clinical decision. This model allows Associate Medical Directors to make a difference by supporting over 100M patients annually.

eviCore



WEBFEEDBACK



CHAT WITH US





## Respected clinical expertise

Highly qualified clinical leadership team assures credibility.


Provider-friendly technology, communications and engagement resources promote collaboration and ease market acceptance.



Clinical & Regulatory Guidelines  
8600 W Bryn Mawr Avenue  
South Tower - Suite 800  
Chicago, IL 60631  
P. 773.864.4600  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)



- PA – Prior Authorizations
- PM – Practice Management systems
- ePA – Electronic Prior Authorization
- AUC – Area Under the Curve
- AUC – Appropriate Use Criteria
- CDS – Clinical Documentation Specialist
- AIM Specialty Health ?



jill@youngmedconsult.com  
youngmedconsult@gmail.com

804 Longfellow Drive  
East Lansing, Michigan 48823

(517) 230-9491



**Questions?**

